AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera Biologics (ABCL) stock rose 121% in 3 months, outpacing its industry. The surge was driven by positive phase II data for ABCL635, a treatment for menopause symptoms, and new partnerships. The study met primary endpoints, showing significant reductions in hot flash frequency and severity. Additional data is expected in October. The company also reported strong financial stability and investor confidence.

AbCellera Biologics (NASDAQ: ABCL) will present Phase 2 clinical data for ABCL635 at the 20th World Congress on Menopause. The company's P/S ratio is 52.59, significantly higher than its historical median of 20.67, indicating high growth expectations. Insiders have bought $2.7 million in shares, while some institutional investors have trimmed holdings. The GF Value™ metric suggests the stock is 171.0% overvalued at $11.57 per share.

Trading alerts issued for AbCellera Biologics (ABCL) on NASDAQ. A covered call strategy is recommended for half of the long position. The price target is set at $20. ABCL's stock has recently spiked due to positive phase 2 data for ABCL635.

AbCellera (ABCL) reported Q2 2026 revenue of $4.1M, down from $17.1M YoY, with a net loss of $55.4M. The company advanced its pipeline, including ABCL635, which met primary endpoints in a Phase 2 study, and announced collaborations with Jazz and Vertex Pharmaceuticals, receiving upfront payments totaling $112M. ABCL ended the quarter with $675M in liquidity. Shares are up 16.78% to $12.40.

AbCellera Biologics' stock rose 14.85% to $12.19, a 52-week high, driven by positive Phase 2 trial results for its menopause drug ABCL635 and bullish analyst price target increases. The company's market value reached $3.4 billion, with analysts raising targets to $25. Despite strong gains, the stock is considered overvalued by some metrics. AbCellera also secured collaborations with Vertex and Jazz Pharmaceuticals, bringing in $100 million in upfront payments. The company reported growing revenu

AbCellera Biologics (NASDAQ:ABCL) shares rose about 64% week over week after phase 2 results for ABCL635, a treatment for hot flashes in menopausal women. In 92 postmenopausal patients, hot flash episodes fell 83% versus 33% with placebo. Truist raised its price target to $30 and peak risk-adjusted sales to $1.1B.